ArticleThe plant pathology journal2026
Proteomic Insights into the Antibacterial Mechanism of Brevibacillus brevis HK544 Producing Edeine B1 against Erwinia amylovora.
Article in The plant pathology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Recently, we reported that Brevibacillus brevis HK544, which produces edeine B1 (EB1), exhibits promising antimicrobial activity against plant pathogens. To elucidate its antibacterial mechanisms against Erwinia amylovora, the causal agent of fire blight, we conducted label-free shotgun proteomic analysis of E. amylovora TS3128 treated with B. brevis culture filtrate (CF) or purified EB1. Comparative analysis showed significant (over twofold) changes in 45 of 624 and 81 of 846 quantified proteins following CF and EB1 treatments, respectively. Functional categorization revealed altered abundances of proteins associated with energy production, ribosome biogenesis, and cell wall/membrane/ envelope biogenesis in both treatments. Notably, 42 and 75 translation-related proteins were differentially expressed in CF- and EB1-treated samples, respectively, consistent with the proposed translation-inhibitory activity of EB1. These findings provide insights into the cellular targets and antibacterial mode of action of B. brevis HK544 and EB1, supporting their potential as biocontrol agents against fire blight.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.